Thomas Lineberger
Internal Medicine · Aberdeen, NCNPI 1811932080
Payments from drug & device makers
Across 249 payments — averaging $13.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$625
- Amgen$451
- GSK$344
- AstraZeneca$272
- Pfizer$231
- Boehringer Ingelheim$206
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,44599%
- Education$211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 55 | $625 |
| Amgen | 36 | $451 |
| GSK | 23 | $344 |
| AstraZeneca | 16 | $272 |
| Pfizer | 17 | $231 |
| Boehringer Ingelheim | 15 | $206 |
| AbbVie | 18 | $178 |
| Johnson & Johnson | 5 | $137 |
| Lilly USA, LLC | 9 | $129 |
| Novartis | 9 | $115 |
| Merck | 7 | $96 |
| Bayer | 4 | $81 |
| Amarin Pharma, Inc. | 5 | $70 |
| Abbott | 2 | $63 |
| Boston Scientific | 2 | $62 |
| Mylan Specialty L.p. | 4 | $50 |
| Currax Pharmaceuticals LLC | 3 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $40 |
| Daiichi Sankyo Inc. | 3 | $40 |
| Kowa Pharmaceuticals America, Inc. | 3 | $35 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Ultragenyx Pharmaceutical Inc. | 1 | $34 |
| Eisai Inc. | 1 | $26 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| GE HealthCare | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Radius Health, Inc. | 1 | $14 |
How this compares
$3,466 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 13 | $14,462 |
| Omeprazole | 18 | $320 |
| Tamsulosin Hcl | 12 | $256 |
| Atorvastatin Calcium | 21 | $224 |
| Pantoprazole Sodium | 13 | $215 |
| Losartan Potassium | 15 | $212 |
| Levothyroxine Sodium | 22 | $189 |
| Lisinopril | 15 | $150 |
| Amlodipine Besylate | 24 | $142 |
| Metformin Hcl | 16 | $111 |
| Gabapentin | 11 | $102 |
| Rosuvastatin Calcium | 14 | $92 |
| Atenolol | 12 | $90 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $231 | $14,46213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Aberdeen
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
- Wayne HarperRaleigh$6.7M
- Joseph MoranStatesville$6.7M
- April SalamaDurham$6.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.